The study pooled data from 4 clinical trials to gain insight into surgical outcomes in this complex population.
Emicizumab can be an effective treatment strategy for hemophilia A prophylaxis, but surgical outcomes for patients on prophylactic emicizumab have not been well-researched. A study published in the journal Blood Advances pooled data from 4 clinical trials to gain insight into surgical outcomes in this population.
Both major and minor surgeries are common for patients with hemophilia A, and these patients are at a greater risk of complications such as bleeding, poor healing, and infection. Hemostatic treatment such as factor VIII (FVIII) replacement or activated prothrombin complex concentrate (aPCC) bypassing agents is an important perioperative strategy, and surgery is especially challenging in those with FVIII inhibitors who do not respond to FVIII replacement. However, it is still possible and can be safe with proper precautions.
“As a result of years of experience of surgeries being performed on patients with hemophilia A with the use of FVIII and bypassing agents to achieve hemostasis, although there is no uniform approach to perioperative management, there now exists a wealth of expert guidance, and even major surgeries can be safely performed on patients with hemophilia A with or without FVIII inhibitors,” the authors wrote.
Emicizumab, a more recently approved bispecific humanized monoclonal antibody for bleeding prevention, is currently recommended as prophylaxis for patients with or without FVIII inhibition in hemophilia A. The HAVEN 1-4 clinical trials (NCT02622321, NCT02795767, NCT02847637, NCT03020160) showed emicizumab to be safe and effective in adults, adolescents, and children with hemophilia A, but there are limited data on emicizumab prophylaxis in patients undergoing minor or major surgeries. “Such data would be of great clinical interest and may inform development of surgical guidelines in the future,” the authors noted.
Of the 399 patients who received emicizumab in the trials, 126 (31.6%) had at least 1 surgery, and 43 (10.8%) had 2 or more. A total of 69 patients (55.6%) who were receiving emicizumab had FVIII inhibitors at the time of study entry. The median age of patients at surgery was 33 years, and the median exposure to emicizumab ahead of surgery was 278 days.
There were 233 surgeries during the trials, including 215 minor and 18 major procedures. Of the minor surgeries, 141 (65.6%) were done without additional prophylaxis, and 121 of the surgeries done without additional prophylaxis (85.8%) were not associated with post-operative bleeding incidents. The number of doses of FVIII or bypassing agents in patients with bleeds after minor surgery was typically low, which suggests the incidents could be controlled quickly and effectively.
Major surgeries were mostly managed with additional prophylactic factor concentrate, which was used in 15 of the 18 major surgeries (83.3%). Of the major surgeries overall, 12 (80%) were not associated with bleeds during or after surgery. None of the surgeries led to death, thrombosis, thrombotic microangiopathy, or FVIII inhibitor development in the trials.
Overall, the pooled data show that surgery can be performed safely in patients who are on emicizumab prophylaxis for hemophilia A.
“Data on surgical experience in patients with hemophilia A on emicizumab continues to grow, and the results concur with those presented here: minor and major surgeries can be performed safely in patients with hemophilia A with or without FVIII inhibitors,” the authors wrote. “To date, there has only been a single prospective clinical trial published, with evidence mainly coming from reviews of medical records and observational studies.”
A notable limitation is that the HAVEN trials were not designed to analyze surgical outcomes and did not have surgical end points. Individuals with major planned surgeries were also excluded from the studies, limiting both the amount of data on major surgeries and the generalizability of the findings in real-world settings.
Future research could help add evidence to the pool and assist in the formation of surgical guidelines for patients with hemophilia A on emicizumab prophylaxis.
Reference
Kruse-Jarres R, Peyvandi F, Oldenburg J, et al. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Adv. Published online August 8, 2022. doi:10.1182/bloodadvances.2022007458
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
Health Equity, Accessibility Essential to Supporting Women Affected by Hemophilia
May 10th 2024Due to often being overlooked as only carriers of hemophilia, the review authors sought to highlight the needs of female caretakers for patients with the disorder and the possibility of women themselves being affected by it.
Read More
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More
Review: One-Shot Etranacogene Dezaparvovec Represents Game-Changing Gene Therapy for Hemophilia B
May 3rd 2024More than 20 years of gene therapy clinical research have led to etranacogene dezaparvovec’s use in hemophilia B, according to authors of a recent review—and it takes its place in a line of current and potentially many future genomic medicines for a range of diseases.
Read More
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More